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Personalized Medicine, Mayo, and the Uncertain
Future of Integrated Health Care
Peter S. Selness*
Personalized medicine is a dynamic and rapidly evolving
approach to healthcare that promises to revolutionize the
practice of medicine. Personalized medicine allows practitioners
to tailor individualized medical treatments to patients based
upon their unique genetic code and eliminates the old one-size-
fits-all approach to healthcare.1 There are numerous benefits
offered by such an approach, but the recent holding in Mayo
Collaborative Services v. Prometheus Laboratories, Inc.
[hereinafter Mayo] poses a substantial threat to future
development in this area of medicine.2 Mayo held that a patent
claiming a diagnostic method for determining the proper dosage
of a medication was invalid because it claimed an underlying law
of nature.3 This holding has the potential to make patenting
personalized medicine methods extremely difficult under 35
U.S.C. § 101 as many of these methods are closely tied to an
underlying law of nature.4 With personalized medicine methods
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1. Gary E. Marchant, Personalized Medicine and the Law, ARIZ. ATT’Y,
Oct. 2007, at 12, 13.
2. See generallyMayo Collaborative Servs. v. Prometheus Labs., Inc., 566
U.S. 66, 66 (2012).
3. See id. at 66.
4. See 35 U.S.C. § 101 (2012) (describing the boundaries of patentable
subject matter); see also Christopher Bergin, Take Off Your Genes and Let the
Doctor Have A Look: Why the Mayo and Myriad Decisions Have Invalidated
Method Claims for Genetic Diagnostic Testing, 63 AM. U. L. REV. 173, 200 (2013)
(explaining that a combination of the Mayo and Ass’n for Molecular Pathology
v. Myriad Genetics, Inc. decisions “have likely eliminated genetic diagnostic
methods as patentable subject matter under § 101”).
788 MINN. J.L. SCI. & TECH. [Vol. 18:2
struggling to fall within the bounds of patentable subject matter,
companies’ ability to turn a profit on expensive research and
development efforts becomes questionable.5 Without the profit
protection granted to companies by a patent, other options need
to be explored to ensure that research and development in the
field of personalized medicine continues.
This Note seeks to examine the field of personalized
medicine, identify any issues that may lead to future research
stagnation, and propose several solutions to those issues. Part I
will cover relevant background information on DNA, describe
the danger posed by Mayo to the field of personalized medicine,
and describe how personalized medicine operates as a new
approach to healthcare. Part II will explain why the field of
personalized medicine is threatened and propose ways to lessen
the impact of Mayo. Part III will then describe ways to
incentivize future research in this field without resorting to
patent protection. This Note will then conclude by stating that
the hazards discussed substantiate a significant threat to
personalized medicine and several or all proposed solutions need
to be adopted to ensure that research continues to develop in this
field.
I. BACKGROUND
The background section will explain the basics of
personalized medicine and the law affecting it. First, a brief
explanation of DNA and its basic functions will be discussed to
provide insight into the genetic component of personalized
medicine. Second, a general overview of personalized medicine
and its benefits to society will be described. Third, the
methodology of personalized medicine will be analyzed. Fourth,
the patentability of personalized medicine methods prior to
Mayo will be explored to summarize the law of that time. Lastly,
the Mayo decision will be summarized.
5. The Promise – and Perils – of Personalized Medicine,
KNOWLEDGE@WHARTON (Dec. 19, 2012), http://knowledge.wharton.upenn.edu
/article/the-promise-and-perils-of-personalized-medicine/ (explaining that “the
financial challenge is complicated by the motivations of profit-making
enterprises . . . [because] companies have to recoup the development costs and
see corporate profits”).
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A. BACKGROUND ON DNA
Understanding Mayo and the implications it may have for
the future of personalized medicine requires a basic
understanding of genetics and the role DNA plays in heredity.
“DNA, or deoxyribonucleic acid, is the hereditary material in
humans and almost all other organisms.”6 DNA is comprised of
four basic building blocks called nucleotides, “adenine (A),
guanine (G), cytosine (C), and thymine (T).”7 Between these four
chemical bases, thymine pairs with adenine and cytosine pairs
with guanine.8 The binding portions of these nucleotides are
attached to a backbone structure comprising a phosphate and
sugar molecule.9 Covalent bonds between the sugar group of one
nucleotide and the phosphate group of another gives rise to long
chains of many nucleotides.10
The chains of nucleotides also bind with their matching base
pairs through hydrogen bonds, giving rise to a macro structure
consisting of two sugar phosphate backbones with nucleotide
base pairs holding the chains together through hydrogen
bonding.11 The base pair bonding within the interior of the
structure may be thought of as “steps” in a chain.12 The hydrogen
bonding patterns of these steps coupled with other
intermolecular forces also cause the overall macro structure to
twist, and thus take on the famous double helix structure DNA
is known for.13 “A good analogy for understanding DNA pairing
is to think of a spiral staircase . . . [with] [e]ach step . . . bordered
by two handrails.”14 The end result is a double helix consisting
of two sugar phosphate backbones with hydrogen bound base
pairs facing the interior and holding the structure together.15
6. What Is DNA?, U.S. NAT’L LIBR. MED, https://ghr.nlm.nih.gov/primer
/basics/dna (last visited Nov. 8, 2016).
7. Id.
8. See id. (illustrating the patterns of binding between base pairs that
gives rise to the overall structure of DNA).
9. Id.
10. BRUCE ALBERTS ET AL., MOLECULAR BIOLOGY OF THE CELL (4th ed.
2002) (ebook), https://www.ncbi.nlm.nih.gov/books/NBK26821/.
11. See id.
12. A. JAMIE CUTICCHIA, GENETICS: A HANDBOOK FOR LAWYERS 7–8
(2009).
13. ALBERTS ET AL., supra note 10.
14. CUTICCHIA, supra note 12.
15. ALBERTS ET AL., supra note 10.
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“It is because of the physical property of the DNA double-
helix that the laws of genetics are made possible.”16 The
sequence of nucleotides within a strand of DNA acts as a code
containing hereditary information passed on from one
generation to another, as well as the instructions for creating
proteins.17 The process of transcription unzips the double helix
structure, matches each nucleotide with its corresponding pair,
and reproduces a new strand of genetic information called
messenger RNA (mRNA).18Nucleotides from the mRNA copy are
then read in multiples of three and matched with the amino acid
that they code for. The amino acids then bind together as more
are matched with their coding section of mRNA, and a protein
structure is assembled.19 It is through this relationship between
an individual’s genetic code and the creation of protein
structures that DNA is expressed.20
Not all DNA is expressed, however, as some portions do not
lead to the creation of proteins. “The nucleotides that code for
amino acids are ‘exons,’ and those that do not are ‘introns.’”21 In
total, merely two percent of DNA actually codes for creating
proteins.22 The remaining ninety-eight percent of DNA is non-
coding and referred to as introns.23 So far, scientists have largely
been interested in exon sequences of DNA and how genetic
variations therein affect disease.24 “The Centers for Disease
Control and Prevention (CDC) states that nine out of the ten
leading causes of death in the United States have a genetic /
genomic component.”25 Naturally, this relationship between
genetics and disease has been of great interest to researchers
16. See CUTICCHIA, supra note 12, at 7.
17. See id. (explaining that a type of four letter alphabet exists due to the
nature of the nucleotides).
18. See CUTICCHIA, supra note 12, at 9–10 (explaining the fundamentals of
the transcription process and how proteins are created from the underlying
genetic code).
19. Id. at 9.
20. Id. at 8–9.
21. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107,
2109 (2013).
22. Patchen Barss, The Dark Corners of Our DNA Hold Clues About
Disease, SCI. AM. (Dec. 18, 2014), https://www.scientificamerican.com/article
/the-dark-corners-of-our-dna-hold-clues-about-disease/.
23. See id.
24. See, e.g., Myriad Genetics, Inc., 133 S. Ct. at 2109.
25. CUTICCHIA, supra note 12, at 96.
2017] PERSONALIZED MEDICINE 791
and has played a large role in the development of personalized
medicine.
B. OVERVIEW OF PERSONALIZEDMEDICINE
Personalized medicine has been defined by the President’s
Council of Advisors on Science and Technology as “the tailoring
of medical treatment to the individual characteristics of each
patient . . . [and] the ability to classify individuals into
subpopulations that differ in their susceptibility to a particular
disease or their response to a specific treatment.”26 This tailoring
of medical treatment to an individual is based upon the
information contained in their genetic code.27 Human DNA is
roughly 99.9% identical, but the 0.1% that is different may lead
to large differences in an individual’s susceptibility to disease
and response to certain medications.28 An effective dosage of
medication for one patient may have little to no effect on
another.29 By knowing both an individual’s genetic make-up and
the correlation between the presence or absence of certain genes,
some of the guess work in calculating dosages for patients may
be eliminated.30 With personalized medicine, physicians are able
to match a specific individual with the optimal dose of a
medication based on that individual’s genetic code; they can
provide “the right patient with the right drug at the right dose
at the right time.”31
Such capabilities raise the question of what impact
personalized medicine may have on future healthcare. One very
promising benefit to healthcare lies in more favorable patient
26. PRESIDENT’S COUNCIL OF ADVISORS ON SCI. & TECH., PRIORITIES FOR
PERSONALIZED MEDICINE 1 (2008), http://cdm266901.cdmhost.com/cdm/ref
/collection/p266901coll4/id/1735 [hereinafter PRIORITIES].
27. See id. (explaining that physicians’ goals have always been to tailor
medical treatment to the specific needs of the patient, but recent developments
in genomics has vastly changed the scope of what may be accomplished in this
area).
28. KEWAL K. JAIN, TEXTBOOK OF PERSONALIZEDMEDICINE 1 (2009).
29. See PRIORITIES, supra note 26, at 12 (illustrating how the drug warfarin
was traditionally dosed through trial and error due to its widely varying effects
on patients).
30. See U.S. FOOD & DRUG ADMIN., PAVING THE WAY FOR PERSONALIZED
MEDICINE: FDA’S ROLE IN A NEW ERA OF MEDICAL PRODUCT DEVELOPMENT 6
(2013).
31. Id.
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responses to medication.32 Even today favorable responses to
medications occur in a mere 30-70% of individuals.33 With
personalized medicine, this portion of the population could be
isolated to maximize drug effectiveness.34 Unfortunately, the
correlation between an individual’s genotype and the effect of a
particular drug are not so simple. Many other factors “including
age, sex, body weight, nutrition, organ function, infections, [and]
comedications” also play a role, leading to complexities in
predicting drug responses.35 Adding an understanding of genetic
predisposition to this list, however, will still lead to more
favorable medical outcomes and better healthcare for all.36
Additionally, personalized medicine has the potential to:
detect diseases at an earlier stage, reduce adverse drug
reactions, reduce the time and cost of clinical trials, revive failed
drugs, shift the emphasis in healthcare from reaction to
prevention, and reduce the overall cost of healthcare.37 Some of
these promising traits of personalized medicine go hand in hand,
such as switching from reactive to preventative medical care and
an overall decrease in health care costs. Focusing on
preventative medicine stems from “the ability to use molecular
markers that signal disease risk or presence before clinical signs
and symptoms appear.”38 Such a focus prevents diseases from
reaching more serious stages, results in less medical treatment,
32. See Wolfgang Sadee & Zunyan Dai, Pharmacogenetics/Genomics and
Personalized Medicine, 14 HUM. MOLECULAR GENETICS 207, 207–09 (2005).
33. Id. at 208 (explaining that a significant portion of the population
experiences adverse effects from drug exposure, causing “a poor risk/benefit
ratio for a diverse patient population”).
34. See, e.g., id. at 207 ( “If the frequency of an adverse event can be reduced
from 5[%] to 2%, by excluding 10% of the targeted population, a drug gains a
more favorable risk/benefit ratio and could advance to first-choice treatment,
thereby gaining market share.”).
35. See id. (explaining that the field of pharmacogenomics attempts to
integrate genetic factors into this list to further the effectiveness of personalized
medicine).
36. See id.
37. Edward Abrahams, Exec. Dir., Personalized Med. Coal., Presentation
at the American Association of Clinical Chemistry Annual Meeting:
Personalized Medicine: The Changing Landscape of Healthcare 5 (July 14,
2007).
38. PERSONALIZEDMED. COAL., THE CASE FOR PERSONALIZEDMEDICINE 8
(4th ed. 2014), http://www.personalizedmedicinecoalition.org/Userfiles/PMC-
Corporate/file/pmc_the_case_for_personalized_medicine.pdf.
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and lowers the overall cost.39 These and other benefits make the
expansion of personalized medicine an obvious asset to society.
C. PERSONALIZEDMEDICINE AS AMETHOD
The field of personalized medicine may be thought of as both
a diagnostic and therapeutic method for the purposes of
patentable subject matter.40 Personalized medicine has the
potential to change the present healthcare system into
integrated healthcare.41 “Advances in medical genetics,
molecular diagnostics, and genome-based medicines will enable
integrated healthcare systems incorporating genetic screening,
preven[]tion, diagnosis, therapy, and monitoring.”42 Such a
method will allow physicians to provide comprehensive care for
patients in a more effective and cost efficient manner.43
Integrated healthcare may be thought of as a unique
approach to healthcare consisting of individual steps. The
screening step of this method would detect genetic
predisposition risk factors for diseases.44 This step may then be
followed by a disease predictive gene testing step to predict
“those at risk of developing a certain disease.”45 Once a
predisposition to disease has been identified, an early prevention
step may be employed to either slow or prevent the disease’s
development.46 Such a step may include correcting the risk
factors already present, or engaging in preemptive treatment.47
Lastly, when a disease has manifested itself in a patient,
therapy may begin subject to continual monitoring.48
Integrated healthcare is the future of personalized
medicine, but the current methods employed are somewhat more
simplistic. Personalized medicine today generally entails
“methods involving diagnostic testing and treatment
39. See id. at 8–9 (explaining that early detection can also eliminate the
need for further costly and invasive diagnostic testing later).
40. KEWAL K. JAIN, TEXTBOOK OF PERSONALIZED MEDICINE 55 (2d ed.
2015).
41. JAIN, supra note 28, at 54.
42. Id.
43. Id.
44. See id. at 55.
45. Id. at 54.
46. Id. at 56.
47. Id.
48. Id.
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administration steps.”49 Such a system is aptly illustrated by
Mayo where the patent in question had “claims covering
processes that help doctors who use thiopurine drugs to treat
patients with autoimmune diseases determine whether a given
dosage level is too low or too high.”50 In relation to drug dosing,
the basic method utilized consists of administering the drug to
the patient and determining the level of resulting metabolite in
the patient’s bloodstream.51 Despite the apparent simplicity, the
method inMayo is of great importance for personalized medicine
and laid the foundation for future integrated healthcare
systems.
D. PRE-MAYO DECISION PATENTABILITY IN PERSONALIZED
MEDICINE
Several cases addressed the patentability of diagnostic
methods and laws of nature prior toMayo, and came to differing
conclusions about the scope of patentable subject matter.
Diamond v. Chakrabarty established the general proposition of
the time that “Congress intended statutory subject matter to
‘include anything under the sun that is made by man.’”52 In
Chakrabarty, a plasmid was spliced into a bacterium which then
allowed it to degrade hydrocarbon compounds.53 Chakrabarty’s
patent application consisted of three claims, one of which
claimed the bacterium itself.54 The Supreme Court held that the
bacterium was patentable subject matter under 35 U.S.C. § 101
and interpreted the terms “manufacture” and “composition of
matter” broadly, so as to avoid the bar on patenting laws of
49. Erik P. Harmon, Promoting the Progress of Personalized Medicine:
Redefining Infringement Liability for Divided Performance of Patented
Methods, 42 HOFSTRA L. REV. 967, 970 (2014).
50. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66, 72
(2012).
51. See id. at 74–75 (listing the steps of the claims involved in the Mayo
patent).
52. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
53. See id. at 305 (explaining that the bacterium was human made and
possessed characteristics like no other bacteria found in nature).
54. See id. at 305–06 (showing that three claims were scrutinized in this
decision: a process claim for creating the bacterium, a claim for an inoculum,
and a claim to the bacterium itself). Only the third claim was rejected by the
Patent Office because bacteria are a product of nature. Id.
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nature and naturally occurring products.55 This holding was a
severe blow to the product of nature doctrine, and “led at least
two commentators to declare the product of nature doctrine
effectively a dead letter in biotechnology.”56 It also had a direct
impact on gene patents as the United States Patent and Trade
Office (USPTO, or PTO) issued “the first patent covering human
genetic material” shortly after Chakrabarty was decided.57 Since
then, a storm of gene patent applications has withstood the
scrutiny of the USPTO.58
In contrast, method claims prior to Mayo did not enjoy the
same level of freedom and deference to patentability. Under 35
U.S.C. § 101, patentable subject matter includes “any new and
useful process, machine, manufacture, or composition of
matter.”59 These categories are subject to the exceptions in
Diamond v. Diehr, however, which stated that “[e]xcluded from
such patent protection are laws of nature, natural phenomena,
and abstract ideas.”60 In Diehr, a patent was found valid by the
Court despite relying on the use of a mathematical equation,
which is commonly classified as a law of nature.61 Despite the
holding in Diehr, many other method patents have been held
invalidated based on the abstract idea exception to § 101.62
55. See id. at 303; 35 U.S.C. § 101 (2012) (explaining three relevant points
addressed when interpreting the language of the 1930 Plant Patent Act and 35
U.S.C. § 101).
56. Jonah D. Jackson, Something Like the Sun: Why Even “Isolated and
Purified” Genes Are Still Products of Nature, 89 TEX. L. REV. 1453, 1455 (2011).
57. Id. at 1454.
58. Id. at 1454–55.
59. 35 U.S.C. § 101 (stating broadly the categories of patentable subject
matter, subject to several exceptions).
60. Diamond v. Diehr, 450 U.S. 175, 185 (1981). Diehr had claimed a
process for curing rubber utilizing the Arrhenius equation for calculating ideal
rubber curing temperatures. Id. at 177–78 (explaining that the method utilized
the Arrhenius equation to constantly determine the ideal temperature for the
rubber molding process and the amount of time remaining before the rubber
press was to open).
61. See id. at 175.
62. See, e.g., Bilski v. Kappos, 561 U.S. 593 (2010); Parker v. Flook, 437
U.S. 584 (1978); Gottschalk v. Benson, 409 U.S. 63 (1972) (illustrating examples
of method claims that were determined to be unpatentable subject matter based
on an abstract idea). Furthermore, these cases show that utilizing a law of
nature in a method is by itself insufficient to pass the § 101 bar on subject
matter patentability. Bilski, 561 U.S. at 593; Parker, 437 U.S. at 584;
Gottschalk, 409 U.S. at 63.
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Several trends have emerged from the rejection of method
patents based on abstract ideas. First, method claims that
largely employ mental steps are generally ruled unpatentable
subject matter.63 Granting patents on purely mental processes
has obvious negative connotations, and enforcing such patents
would be nearly impossible. Second, method claims applying a
law of nature are rarely valid.64 When applying laws of nature,
the patent claim must include something substantially more
novel than the mere application of an existing law.65 Lastly,
creating a software program to digitize a method grants no
additional level of novelty than would be present if the same
process were carried out physically.66 Taking a previously
physical or mental process and coding it to be performed by a
computer changes the medium of the process, not its level of
novelty.67 These three general trends concerning method claims
had been well established prior to Mayo, and ultimately played
an important role in the holding.
E. MAYO SUMMARY
In Mayo, the Supreme Court held that a diagnostic method
for determining the proper dosing of thiopurine drugs was
invalid as it impermissively claimed the “underlying laws of
nature themselves.”68 Prometheus Laboratories held two
patents concerning the use of thiopurine drugs for treatment.69
63. See Bilski, 561 U.S at 595 (“Petitioners seek to patent both the concept
of hedging risk and the application of that concept to energy
markets . . . however, these are not patentable processes but attempts to patent
abstract ideas.”); Gottschalk, 409 U.S. at 68 (explaining that the method of
hedging risk set forth in Bilski was unpatentable subject matter as it was
merely a way of thinking for investment purposes). Furthermore, Gottschalk
shows how a patent claim for a method of converting binary-coded decimal
numbers into pure binary form by utilizing a computer was found to be non-
patentable subject matter as it was an abstract idea. Gottschalk, 409 U.S. at 68.
64. See Parker, 437 U.S. at 594–95 (illustrating how a method of constantly
updating alarm limits on a catalytic conversion was unpatentable subject
matter as it merely applied a known law of nature to a known process).
65. Id. at 590 (explaining that merely including a final step of applying a
law of nature does not make it patentable subject matter under § 101).
66. See Gottschalk, 409 U.S. at 67 (noting that the mathematical process at
issue could be performed by older analog computers and by hand).
67. Id.
68. See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66,
92 (2012).
69. See id. at 67.
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These patents were based upon the metabolization of thiopurine
when ingested by the human body.70 The body metabolizes
thiopurine drugs at different rates, resulting in different levels
of metabolite in the patient’s bloodstream.71 Such differences in
metabolization rates leads to difficulty in treating patients with
the correct dosage of thiopurine.72 The patent claimed a method
for treating patients with thiopurine drugs based on the
relationship between the level of metabolite in the patient’s
bloodstream and the resulting effectiveness or ineffectiveness of
the treatment.73 The method claims being challenged are largely
set forth as follows:
Each claim recites (1) an “administering” step—instructing a doctor
to administer the drug to his patient—(2) a “determining” step—
telling the doctor to measure the resulting metabolite levels in the
patient’s blood—and (3) a “wherein” step—describing the metabolite
concentrations above which there is a likelihood of harmful side-
effects and below which it is likely that the drug dosage is ineffective,
and informing the doctor that metabolite concentrations above or
below these thresholds “indicate a need” to decrease or increase
(respectively) the drug dosage.74
The basis for challenging the patents stated that the method
claimed a natural phenomenon relating to “the correlation[]
between thiopurine metabolite levels and the toxicity and
efficacy of thiopurine drugs.”75 The Court agreed and held the
patents invalid because they were largely based upon this
natural phenomena with no other steps adding anything to the
realm of patentable subject matter.76 In so doing, the Court
analyzed each of the steps in the method looking for an inventive
concept that was substantially more than the application of the
natural phenomena, and then viewed the method as a whole
with the same intent.77 This two-step test has come to be called
the Mayo test.
70. Id.
71. Id.
72. Id.
73. Id.
74. Id.
75. Id. at 68 (illustrating that the human body naturally carries out the
process of metabolizing thiopurine drugs in this way whether or not it is part of
a method).
76. Id. (explaining that the court was also cautious to avoid granting
patents on claims that did not genuinely apply the law of nature, but were
merely clever drafting techniques to make it appear so).
77. Id.
798 MINN. J.L. SCI. & TECH. [Vol. 18:2
When applying this methodology, the first “administering”
step was found to merely identify a group that would be
interested in the correlation between metabolite levels in the
patient and the effectiveness of treatment.78 Furthermore, the
Court concluded that a “prohibition against patenting abstract
ideas cannot be circumvented by attempting to limit the use of
the formula to a particular technological environment.”79 The
“wherein” step simply restated the natural law correlating the
effectiveness of treatment with the amount of metabolite
measured.80 The method then relied upon the doctors to use the
law in their decision making process.81 Lastly, the “determining”
step essentially instructed the doctors to measure the resulting
level of metabolite in the patient’s bloodstream.82 Because the
methods and technology used for measuring the metabolite were
already well known and routine, this step added nothing that
was not conventional or obvious.83 The Court then viewed the
method as an ordered combination and still found nothing that
significantly added to the law of nature recited.84 The Court
determined that the process “simply tell[s] doctors to gather data
from which they may draw an inference in light of the
correlations.”85 As such, the claimed method in Mayo was found
to be unpatentable subject matter and the patent was
invalidated.
II. ANALYSIS
Mayo has potential to cause great harm to the field of
personalized medicine, as this part will explain. Part II will
begin by pointing out the specific dangers of Mayo to
personalized medicine. It will then go on to explore the effects of
78. Id. (stating that doctors had been using thiopurine drugs to treat
patients with autoimmune disorders long before this patent emerged).
79. Id. at 78 (internal quotations omitted).
80. Id.
81. Id. (suggesting that such a step boils down to the application of the law
of nature).
82. Id. at 79.
83. Id. (explaining that scientists routinely utilized this method of
measuring metabolite levels when investigating the toxicity of thiopurine
compounds).
84. Id.
85. Id. (concluding that the claims inform a target audience about a natural
phenomenon and contain routine steps already well known by the scientific
community that adds nothing to the claims when viewed as a whole).
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Mayo when coupled with the Myriad decision. Part II will
conclude by analyzing the post-Mayo effects on the patentability
of personalized medicine methods.
A. MAYO’S EFFECT ON PERSONALIZEDMEDICINE PATENTS
Mayo poses a unique danger to the field of personalized
medicine because most personalized medicine patents resemble
a more complicated version of the Mayo patent.86 Personalized
medicine is unique because it is an overarching process of
carrying on healthcare rather than an individual medical
procedure as depicted inMayo.87 It fits into a grey area of patent
law that is neither the simplistic method of administering
medication illustrated by Mayo or a tangible medical invention
such as a medication. Instead, it is a hierarchy of steps involving
known methods of genetic testing and the administration of
existing medication based upon the results of those tests.88 Such
a system has the potential to revolutionize healthcare, but the
current approach to the patentability of methods may make
obtaining patent protection quite difficult.
The first issue raised by Mayo concerns the test set forth by
the Supreme Court for dealing with issues of patentability under
35 U.S.C. § 101.89 This process, known as theMayo test, consists
of two steps for determining if the subject matter in question is
patentable: “(1) ‘whether the claims at issue are directed to one
of those patent-ineligible concepts’; and if so, then (2) ‘whether it
contains an “inventive concept” sufficient to “transform” the
claimed abstract idea into a patent-eligible application.’”90 This
was the two-step test used to determine that there was no
sufficient inventive concept in the scrutinized claims of Mayo.91
Since its establishment, theMayo test has invalidated numerous
86. See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66
(2012).
87. See supra Section I.C.
88. See PRIORITIES, supra note 26 (explaining the basics of the personalized
medicine process).
89. See 35 U.S.C. § 101 (2012) (explaining what constitutes patentable
subject matter).
90. Steven Swan, Plugging the Rabbit Hole: The Supreme Court’s Decision
in Alice, 2016 UTAH L. REV. 891, 893 (2016) (quoting Alice Corp. Pty. Ltd. v.
CLS Bank Int’l, 134 S. Ct. 2347, 2355–57 (2014)) (explaining that theMayo test
was first laid forth in Mayo, but more formally codified in later cases such as
Alice).
91. See Mayo, 566 U.S. at 66.
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other patents for lack of an “inventive concept sufficient to
transform the claimed abstract idea into a patent-eligible
application.”92
The Mayo two-step test may potentially invalidate a wide
array of personalized medicine patents to which it is applied.
Personalized medicine combines already established genetic
tests, natural phenomena, and the distribution of existing
medications.93 Step one of theMayo test will be satisfied because
personalized medicine patents incorporate both laws of nature
and abstract ideas.94 Step two will then be applied to search for
an inventive concept when viewing the claim as a whole.95 It is
likely that personalized medicine patents will also have issues
passing this second step. Personalized medicine is largely based
upon statistical correlations between subpopulations expressing
a particular genetic variation and the resulting efficacy of
medications.96 This statistical correlation results from an
underlying law of nature, leading to complications with
patentability under theMayo test. Thus, the resulting similarity
between the claims invalidated in Mayo and the claims of
personalized medicine patents will likely sway court opinion
toward invalidation.97
The problem with the Mayo test lies in its failure to
appreciate the dramatic impact personalized medicine will have
on today’s health care system. The truly innovative concept of
personalized medicine lies in its ability to switch healthcare
from reactive to preventative medicine tailored to each
individual.98 However, a simplistic application of the Mayo test
to personalized medicine claims would likely fail to capture this
innovative concept. As such, the Mayo test poses a significant
92. Alice, 134 S. Ct. at 2355; see, e.g., Ariosa Diagnostics, Inc. v. Sequenom,
Inc., 788 F.3d 1371, 1377–79 (Fed. Cir. 2015), cert. denied, 136 S. Ct. 2511
(2016); OIP Techs., Inc. v. Amazon.com, Inc., 788 F.3d 1359, 1362 (Fed. Cir.
2015), cert. denied, 136 S. Ct. 701 (2015).
93. See supra Section I.C.
94. See Alice, 134 S. Ct. at 2355 (illustrating the criteria that trigger step
one of the Mayo test).
95. See id. (showing that step two is an exception to invalidation under step
one of the Mayo test, but case law has shown that it is a relatively high bar to
meet).
96. See Mayo, 566 U.S. at 66.
97. See id.
98. Marchant, supra note 1, at 14.
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threat to personalized medicine patents and may potentially
invalidate the resulting method claims.
The second issue facing personalized medicine lies in the
direct implication of declaring personalized medicine patents
unpatentable subject matter. Patents are enabled under Article
I, Section 8 of the United States Constitution.99 The relevant
language states that “Congress shall have power . . . [t]o promote
the Progress of Science and useful Arts, by securing for limited
Times to Authors and Inventors the exclusive Right to their
respective Writings and Discoveries.”100 The patent system, as it
is today, has been derived directly from this constitutional
language, and has been vital in promoting the development of
technology.101
The underlying rationale for having a patent system, as
stated directly in the Constitution, is to promote the progress of
technological advancement.102 This purpose may be further
broken down into three theories: reward theory, disclosure
theory, and specialization theory.103 Reward theory considers
patents to be a motivating factor for inventors to develop new
technologies.104 From a reward theory perspective, “patents are
utilitarian tools employed via government action to enlist
potential inventors in serving societal needs.”105 Disclosure
theory focuses on the societal gain experienced from forcing
inventors to disclose the inner workings of their inventions to
the rest of the world as a result of the patent application
process.106 Lastly, specialization theory states that patents help
with the organization and specialization of individuals in
99. U.S. CONST. art. I, § 8.
100. Id. (showing that the importance of patents to the development of
technological discoveries has long been recognized, dating all the way back to
the United States Constitution).
101. See Richard S. Gruner, Why We Need A Strong Patent System and
When: Filling the Void Left by the Bilski Case, 28 SANTA CLARA COMPUTER &
HIGH TECH. L.J. 499, 499–503 (2012).
102. See id.
103. Gruner, supra note 101, 504–13.
104. See id. at 504–05 (explaining that reward theory is the oldest and most
economically based theory for having a patent system).
105. Id. at 505.
106. See id. at 508 (stating that in many cases, inventors would otherwise
keep the specifics of their inventions to themselves and others would be unable
to benefit from the discoveries made).
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bringing products to market.107 For the purposes of personalized
medicine, reward theory and disclosure theory are most relevant
and play the most significant role in future technological
advancement.108
Applying the Mayo test to personalized medicine patents
will likely lead to the conclusion that those patents cover
unpatentable subject matter, but why is this important? It has
been argued that patenting discoveries in the field of
personalized medicine or genetics is unnecessary or may even
inhibit future innovation.109 However, there are also several
perspectives contrary to this point of view. The first argument in
favor of patent protection for personalized medicine is based on
the reward theory. Private companies are profit driven, and
without a reasonable probability of profiting from research
expenses, it is unlikely that any research will be conducted in
the first place.110 Patents play a vital role in a company’s ability
to ensure that they will be able to recoup the losses they sustain
from research.111 Furthermore, from an investor’s perspective,
“patents serve as a leading indicator of profits.”112 Attracting
investors to a company also plays a significant role in a
company’s success, and “[c]ompanies with strong patent
portfolios routinely outperform the S&P 500.”113 The bottom line
is that patent protection for a company’s inventions matters, and
with little hope of obtaining a personalized medicine patent,
research in this area will likely dwindle.
The second argument in favor of granting personalized
medicine patents is based upon the disclosure theory. If a
company is unable to obtain patent protection for their
107. See id. at 511–12 (explaining the benefits patents confer to businesses
in the organizational structure of the company).
108. See id. at 507, 509 (emphasizing the importance of reward and
disclosure theories for future advances in patentable materials).
109. Marchant, supra note 1, at 19 (explaining that “excessive patenting in
the genomics field . . . is impeding innovation by creating . . . a thicket of
overlapping patent rights [that] precludes anyone from fully developing
the patented technologies”).
110. See Louise Basenese, Patents Mean Profits . . . for Firms and Investors,
WALL ST. J. (July 14, 2016), https://www.wallstreetdaily.com/2016/07/14/asia-
tech-patents/ (explaining that there are “wars” being fought in Asia over patent
protection due to what patent protection means for the profitability of a
company).
111. Id.
112. Id.
113. Id.
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inventions, a logical alternative form of protection is resorting to
trade secret.114 Resorting to trade secret protection is less
beneficial to society as it prevents the flow of information
obtained from discoveries and does not allow others to build
upon those discoveries.115 Patents have the “twin purposes of
encouraging new works and adding [knowledge] to the public
domain.”116 If trade secret protection becomes widely utilized by
personalized medicine researchers due to the unobtainability of
patent protection, no new knowledge will be added to the public
domain and the technological progress within this field will be
greatly slowed.
Mayo will have a direct impact on the future development of
personalized medicine unless patent law in this area is modified
or alternative forms of incentives are pursued. TheMayo test as
adopted by the Supreme Court is essentially a death sentence
for personalized medicine patents, and will continue to affect the
industry for years to come. In an attempt to remain profitable,
companies will either abandon research in this area or seek
trade secret protection to ensure no competitors benefit from
their research. Either way, personalized medicine will be
negatively impacted by Mayo to the detriment of society.
B. MYRIAD’S IMPLICATIONS COUPLED WITHMAYO
Shortly after Mayo, a second decision was handed down by
the Supreme Court that also has a direct impact on the field of
personalized medicine.117 Ass’n for Molecular Pathology v.
Myriad Genetics, Inc. [hereinafter Myriad] considered the
patentability of human genes.118 In Myriad, Myriad Genetics
discovered and isolated the location of the BRCA1 and BRCA2
genes.119 These genes held importance as mutations in them had
114. EarthCam, Inc. v. OxBlue Corp., 49 F. Supp. 3d 1210, 1224 (N.D. Ga.
2014) (defining trade secrets as “information . . . which is not commonly known
by or available to the public . . . [which] [d]erives economic value . . . from not
being generally known to . . . other persons who can obtain economic value from
its disclosure or use”).
115. See id. (explaining that the information must be kept with reasonable
efforts at secrecy from others who could economically gain from this information
in order to qualify for trade secret protections).
116. Eldred v. Ashcroft, 537 U.S. 186, 227 (2003).
117. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107,
2107 (2013).
118. Id.
119. Id. at 2112.
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been linked to an increase in both breast and ovarian cancer for
women.120 Knowing the location and the specific nucleotide
sequence of these genes allowed Myriad to develop a medical test
for ascertaining a patient’s risk of developing cancer.121 Myriad
then patented their discoveries, and claimed the BRCA1 and
BRCA2 genes in their patent application.122 Myriad was filed
when the patentability of isolated human DNA was brought into
question for being a product of nature.123 In the end, the Court
concluded that cDNA124 was patentable subject matter, but
isolated DNA was not, as it existed in nature.125
Myriad imposes an additional road block to the
patentability of personalized medicine. Personalized medicine is
based upon the specific genetic code of each individual patient
and any predisposition to disease or the effectiveness of
medication that may result.126 Therefore, one of the steps in a
personalized medicine method requires identifying genetic
mutations that may lead to these predispositions.127 As
previously noted, the personalized medicine method itself will
likely be unpatentable due to Mayo. When seeking an
alternative route to securing patent protection for personalized
medicine methods, companies may have attempted to patent the
genes utilized as part of each method. Holding a gene patent
(when still allowable before Myriad) allowed the patentee to
prevent others from isolating and manipulating the patented
gene outside the body, and prevented competitors from
performing genetic testing on that gene. Such a patent would
have allowed the patent owner to exclude others from conducting
genetic tests on those genes and would have made carrying out
the personalized medicine method impossible. However, because
of Myriad, this approach is no longer possible and personalized
medicine methods cannot obtain patent protection through the
120. Id.
121. Id. (stating that a mutation in one of these genes could signal up to a
sixty-five percent increase in the risk of developing cancer).
122. Id. at 2113 (explaining that Myriad claimed both the isolated DNA and
cDNA of the BRCA genes).
123. See id. at 2114.
124. Id. at 2115.
125. Id. at 2116 (explaining that Myriad had not invented or discovered the
isolated DNA, they had merely located its position on the BRCA genes).
126. JAIN, supra note 28, at 2.
127. See JAIN, supra note 40, at 55.
2017] PERSONALIZED MEDICINE 805
genes of interest, nor the method used.128 Thus, Mayo and
Myriad together block many avenues to patent protection for
personalized medicine methods.
C. POSTMAYO DECISION
Mayo was decided several years ago, and the effects it has
had on diagnostic method patents, such as those in the field of
personalized medicine, have been immense.129 Myriad also
illustrates a sharp change in the Supreme Court’s view of
patents involving a genetic component, and was a significant
departure from the “anything under the sun” philosophy held
before.130 Besides Myriad, however, several other cases
illustrate just how significant the impact of Mayo has been. In
Alice Corp. Pty. Ltd. v. CLS Bank International [hereinafter
Alice], the two-step test conceptualized in Mayo was solidified
and applied to another method claim.131 The patent at issue in
Alice concerned a computer system that acted as an
intermediary to negate settlement risk for two parties.132 The
patent claimed “a method for exchanging financial
obligations.”133 The Court applied the Mayo two-step test to this
claim and found that it was directed toward the abstract idea of
intermediary settlement, and that digitizing this idea added
nothing to transform an abstract idea into patent-eligible subject
matter.134 Alice thus further solidified and expanded the bounds
of the Mayo test and reaffirmed the policy of subjecting method
claims to additional scrutiny when abstract ideas are present.
In addition to Alice, Ariosa Diagnostics, Inc. v. Sequenom,
Inc. invalidated yet another diagnostic method patent,135 and
128. See Myriad Genetics, Inc., 133 S. Ct. at 2107.
129. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66, 91
(2012).
130. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) (internal quotations
omitted); see also Myriad Genetics, Inc., 133 S. Ct. at 2109.
131. Alice Corp. Pty. Ltd. v. CLS Bank Int’l, 134 S. Ct. 2347, 2350–51 (2014).
132. See id. at 2349 (explaining that the computer system would act as a
third party that could assure the other parties that all financial obligations
would be fulfilled).
133. Id.
134. See id. at 2350 (stating that the same issue from Mayo was present in
this case and that applying an abstract idea is not enough to obtain patent
protection).
135. Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371, 1378 (Fed.
Cir. 2015), cert. denied, 136 S. Ct. 2511 (2016).
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made obtaining such patents even more difficult. Ariosa
scrutinized a patent that utilized cell-free fetal DNA (cffDNA) in
a woman’s bloodstream to determine if she is pregnant.136 The
patent claimed a method for obtaining a sample of cffDNA,
amplifying the sample, detecting the sample, and then
determining certain characteristics of the fetus such as gender
and possible genetic defects.137 The Court applied the Mayo test
and found that the method began and ended with a naturally
occurring phenomenon: the presence or absence of cffDNA in the
mother’s bloodstream.138 Moving on to step two of theMayo test,
the Court found that the method simply applied commonly
known techniques to a naturally occurring phenomenon, and
that the only innovation stemming from the patent came from
the discovery of cffDNA.139 The Court thus invalidated the
patent for claiming unpatentable subject matter.140Of particular
relevance to personalized medicine, however, Sequenom argued
that their patent should be upheld as it “combined and utilized
man-made tools of biotechnology in a new way that
revolutionized prenatal care.”141 A very similar argument may
be made for the effects of personalized medicine on general
healthcare, but the Court found such revolutionary discoveries
still unworthy of patent protection.142
Since Mayo was decided, further decisions have continued
to chip away at the chances of a personalized medicine method
obtaining a patent. The Mayo test has become more broad and
encompassing, striking down more and more diagnostic method
patents. These effects have also been felt within the United
States Patent and Trade Office. “[F]ollowing a key Supreme
Court decision in 2012, the US Patent and Trademark Office
(USPTO) was nearly four times more likely to
deem . . . [applications of laws of nature] unpatentable — and
applicants were less than half as likely to overcome those
136. Id. at 1373.
137. See id. (explaining that only the method was claimed in the patent, not
the cffDNA itself).
138. See id. at 1376.
139. See id. at 1377 (stating that discovering cffDNA was the only innovative
part of the method, but as cffDNA is naturally occurring it is not patent eligible
subject matter).
140. See id. at 1378.
141. Id. at 1379 (internal quotations omitted).
142. See id.
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rejections.”143 Indeed, some view theMayo decision as “the death
knell for patents relating to personalized medicine, diagnostics,
and biotechnology.”144
III. SOLUTIONS FOR INCENTIVIZING FUTURE
RESEARCH
Part III will attempt to address the issues facing the field of
personalized medicine raised in Part II. It will start by proposing
possible forms of claims drafting that may confer a greater deal
of patentability on personalized medicine methods. Next, the
benefits of increased funding for a central genetic database will
be discussed. Short periods of regulatory exclusivity from the
Food and Drug Administration (FDA) will also be analyzed as a
possible way to grant a temporary market monopoly to the
developer of a personalized medicine method without issuing a
patent. Also, a cash incentive program will be explored as a way
to fill in present short comings in the patent system. Lastly, this
Part will conclude by proposing a modified compulsory licensing
system to further incentivize research in the field of personalized
medicine.
A. NEW FORMS OF CLAIMS DRAFTING
One possible avenue for circumventing the statutory bar
imposed by 35 U.S.C. § 101 on unpatentable subject matter lies
in new and innovative forms of drafting patent claims. It may be
possible to obtain a patent on a personalized medicine method if
the language of the patent’s claims provides an avenue for step
two of the Mayo test to find a substantially innovative concept.
The chances of creative lawyering being a viable solution in the
eyes of the Court depends upon how broadlyMayo is interpreted.
If Mayo leads courts to presume that diagnostic method claims
are unpatentable subject matter as a rule with few exceptions,
then no amount of creative claims drafting will be able to
convince them otherwise. As the lower court’s interpretation of
Mayo is still being established, however, some methods of claims
drafting may aid in the patent approval process.
143. Heidi Ledford, US Personalized-Medicine Industry Takes Hit from
Supreme Court, NATURE (Aug. 17, 2016), http://www.nature.com/news/us-
personalized-medicine-industry-takes-hit-from-supreme-court-1.20436.
144. Sanjesh P. Sharma, Patent-Eligible Subject Matter in Light of Mayo v.
Prometheus, 24 INTELL. PROP. & TECH. L.J. 9, 9 (2012).
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First, guidance from the PTO has stated that claiming a law
of nature or other exception to patentable subject matter is
impermissible, and claims “should include other elements or
combination of elements such that, in practice, the claimed
product or process amounts to significantly more than a law of
nature[.]”145 The wording from this memorandum indicates that
certain combinations of elements added to a claim involving a
law of nature may be enough to transform the nature of the claim
to cover patentable subject matter.146 Toward this end, the
inclusion of nonobvious elements in the claim may well aid in
this transformation.147 In theMayo decision, the “Court found it
relevant and important that the additional steps . . . were ‘well
understood, routine, and conventional.’”148 Therefore, by
including non-routine or unconventional steps in the diagnostic
method, it may be possible to pass step two of the Mayo test
when viewing the claim as a whole.149 Possibilities for achieving
this in the field of personalized medicine include using a novel
genetic test for the screening step, using a novel antibody for the
monitoring step, or administering a novel medication for the
therapy step. As such, the inclusion of non-obvious elements in
a diagnostic method has potential to transform the claim into
patentable subject matter.
A second way to draft more patentable subject matter
friendly claims lies in narrowing the scope of those claims.150 In
Mayo, the Court viewed the claims unfavorably because the
breadth of the claims appeared to partially encompass a law of
nature.151 If a claim necessitates the use of a law of nature, “one
must do more than simply state the law of nature while adding
145. Memorandum from Andrew H. Hirshfield, Associate Comm’r, U.S.
Patent & Trademark Office, on Supreme Court Decision in Mayo Collaborative
Services v. Prometheus Laboratories, Inc. to Patent Examining Corps (Mar. 21,
2012), www.uspto.gov/patents/law/exam/mayo_prelim_guidance.pdf.
146. Id.; see Angela L. Morrison, Mayo v. Prometheus: Patent Eligibility of
Claims Covering Natural Laws, 41 COLO. LAW. 77, 82 (2012).
147. See Morrison, supra note 146, at 82.
148. Id.
149. See id. at 82–83.
150. See id. at 83 (stating that it is important to use active steps when
drafting claims and be specific as to what is required by each step).
151. See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66,
72–73 (2012).
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the words ‘apply it.’”152 Narrowing the scope of the claims sets
forth a more specific method with limits on what is being
claimed, and may distance the method from the law of nature.153
While it is important to distance the patent application from
claiming the underlying law of nature, however, this also must
be balanced with the value lost to the patent through excessive
narrowing. For personalized medicine, claims may be narrowed
by stating exactly what genetic test is to be used, what antibody
is to monitor results, and what medication is to be administered
for therapy, based upon specific criteria. Coupling this specificity
with the previously mentioned novel elements may yield a claim
that, when viewed in its entirety, is substantially more than the
application of a natural law and satisfies the Mayo test’s second
step.
A third possibility for drafting claims around the Mayo test
lies in focusing claims on a man-made component integral to the
diagnostic method, rather than the method itself.154 This
approach comes with some obvious limitations, namely, the
method must at some point rely on the use of a man-made
sample. Creation of such a sample for purposes of personalized
medicine would most likely necessitate the binding of DNA
probes to the patient’s genetic material during the genetic
sequencing step.155 Such a step would result in the creation of a
non-naturally occurring complex that could be patented as part
of the method. Despite the Supreme Court invalidating the
machine or transformation test as the sole test of patentability
for methods in Bilski, it was still acknowledged that “the
machine-or-transformation test is a useful and important clue,
an investigative tool, for determining whether some claimed
inventions are processes under § 101.”156 Therefore, including a
step that transforms a sample into something man-made and
152. SeeHirschfield, supra note 145 (explaining that the distinction between
patentable and unpatentable subject matter lies in applying the law in a limited
fashion rather than claiming the law itself).
153. See, e.g., Morrison, supra note 146, at 80.
154. Holly Atkinson et al., Personalized Medicine Patents at Risk: Tips for
Battling Prometheus and Myriad to Obtain Claims to Diagnostics, FINNEGAN
(Mar. 2013), http://www.finnegan.com/resources/articles/articlesdetail.aspx
?news=d71205da-cb48-4827-9a8c-fde729146046.
155. See id. (stating that the creation of a non-naturally occurring antibody-
biomarker complex as an intermediate should convey patentability).
156. Bilski v. Kappos, 561 U.S. 593, 604 (2010).
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non-naturally occurring may give more weight to a finding of
patentability for a diagnostic method claim.
In summary, it may still be possible to obtain a patent for a
personalized medicine method through creative claims drafting
techniques. Such a possibility still depends largely upon the
manner in which the Court interprets and applies theMayo test.
A combination of the discussed techniques may aid in distancing
the patent application from claiming an underlying law of
nature and grant the claims a certain degree of novelty. If
personalized medicine patents remain unobtainable under this
approach, however, other forms of incentives may need to be
explored.
B. INCREASED DEVELOPMENT OF GENETIC DATABASES
Additionally, some “scholars have proposed a variety of fixes
that wouldn’t require overturning Mayo but which might
compensate for its potential negative impact on investment.”157
One method for supporting the field of personalized medicine
without delving into the issue of patentability lies in providing
funding for genetic databases.158 The human genome and the
implications of genetic differences between individuals is an
extremely complex area of science. Sequencing a single patient’s
exome results in roughly sixty million data-points.159 All of that
data must be analyzed to determine the genetic implications for
a single patient. Furthermore, trends in the expression of
specific genetic variations only emerge when dealing with a
large sample size including numerous individuals who share the
same genetic variation. “Ideally, doctors could tap into a single,
large database filled with anonymous genetic information —
biomarkers tied to patient demographics tied to specific drugs
and treatments — to help doctors make decisions about each
individual’s medical path.”160
157. Thomas Cotter, Patent Wars: How Patent Disputes Impact Our Daily
Lives (Nov. 4, 2016) (unpublished book) (on file with Thomas Cotter of the
University of Minnesota Law School).
158. See id. (listing the subsidization of genetic databases among other
suggestions for offsetting the negative impact of Mayo).
159. Vojtech Huser et al., Developing Genomic Knowledge Bases and
Databases to Support Clinical Management: Current Perspectives, 7
PHARMGENOMICS & PERS. MED. 275, 276 (2014), https://www.ncbi.nlm.nih.gov
/pmc/articles/PMC4175027.
160. Dawn McMullan, What Is Personalized Medicine?, GENOME (Jan. 19,
2017), http://genomemag.com/what-is-personalized-medicine.
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Having one central database all practitioners could consult
for guidance in the interpretation of genetic variations would
greatly aid practitioners’ ability to make informed decisions in
the field of personalized medicine.161 Understanding the basics
of what genetic variations mean for an individual’s health is
central to practicing personalized medicine, and having a single
genetic database to aid in physicians’ decisions would lead to
better medical care for all. Databases help in this area because
they reduce the typical number of relevant variants in a patient’s
exome from roughly twenty thousand to a more workable
number.162 Knowing which variants in a patient’s genetic code
carry significance plays a pivotal role in the process of
personalized medicine, and the development of genetic
databases will play a large role in the future success of
personalized medicine.
There are several ways to improve the existing genetic
databases to aid in the development of personalized medicine.
First, all genetic data contained in existing databases should be
consolidated into a single location.163 A recent study concluded
that there are 314 distinct genetic databases maintained by a
variety of institutions.164 Consolidating all the information
contained in these databases into a single, well maintained
database would significantly aid practitioners in their
understanding of genetic variation implications. A second way to
improve the function of genetic databases for personalized
medicine is to tailor the accessibility and interface toward
physicians and genetic counselors rather than researchers.165
Lastly, databases should be adapted to contain information on
not just a patient’s genotype, but also their long term phenotype
to better understand how genetic variants are expressed over a
long period of time.166 Such changes would greatly aid in
161. See Huser, supra note 159, at 275.
162. See id. (stating that unfortunately there is no one central database that
provides a complete set of variants).
163. See id.
164. See id. at 278 (explaining that some of these databases may no longer
be maintained, however).
165. See id. at 281 (stating that a combination of targeting physicians as the
primary platform users and establishing training programs on the platform’s
functions would aid in adapting genetic databases for use in the field of
personalized medicine).
166. See id. at 280 (explaining that such a change raises data privacy issues
that will need to be addressed as patient-level data is retained).
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understanding the genetic component of personalized medicine,
but most likely could only be carried out by government action
due to the size and financial constraints of such a project.
C. SHORT PERIODS OF REGULATORY EXCLUSIVITY
An additional possibility for ensuring sufficient incentive
exists to spur research in the field of personalized medicine lies
in making modifications to the existing regulatory scheme
governing this area. Several organizations play a role in
regulating personalized medicine. The Centers for Medicare and
Medicaid Services (CMS) was established by Congress and
granted the power to regulate “all clinical laboratories
performing genetic testing”167 to ensure compliance with
applicable standards.168 The goal of the CMS was to guarantee
quality in the procedures used for clinical testing.169 As such, the
genetic testing utilized in personalized medicine falls squarely
within the regulatory powers of the CMS.170 This is but a small
portion of a personalized medicine method, however, giving the
CMS a relatively small regulatory role in this area.
The regulatory body tasked with the most significant
responsibility pertaining to personalized medicine is the Food
and Drug Administration.171 The FDA is tasked with the
regulation of all drugs and medical devices.172 The FDA thus
regulates the safety and efficacy of any drugs utilized in
personalized medicine methods, as well as diagnostic testing,
effectively granting it jurisdiction over the entire method.173
Despite regulatory difficulties that most certainly will arise
when applying the current regulatory scheme to personalized
medicine, the FDA has demonstrated an eagerness to tackle the
challenge.174 The FDA has stated: “From FDA’s perspective,
personalized medicine promises to increase benefits and reduce
risks for patients by improving both the safety and efficacy of
167. Regulation of Genetic Tests, NAT’L HUM. GENOME RES. INST. (June 21,
2016), https://www.genome.gov/10002335/regulation-of-genetic-tests/.
168. See 42 C.F.R. § 493.551 (2016) (“CMS may deem a laboratory to meet
all applicable CLIA program requirements.”).
169. See Regulation of Genetic Tests, supra note 167.
170. See id.
171. See id.
172. See id.
173. See id.
174. U.S. FOOD& DRUG ADMIN., supra note 30, at 11.
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medical products.”175 Furthermore, personalized medicine has
the potential to allow medications tailored for use in a particular
population of medical candidates to pass FDA regulatory
processes where the medication may previously have failed to
meet FDA standards under the one-size-fits-all approach.176 As
such, the FDA is in the best position to incentivize continued
research in this area from a regulatory standpoint.177
Per 21 C.F.R. 314.108, a period of exclusivity may be
granted by the FDA to a newly developed drug.178 This period of
exclusivity prevents other drugs similar in composition and
purpose from attaining FDA approval for a set period of time.179
In effect, a market monopoly is granted to the holder of the FDA
exclusive drug as without FDA approval, drugs created by
competitors cannot be marketed to consumers.180 The extent of
the period of exclusivity granted varies depending upon the
chemical composition of the new drug.181 The FDA’s Center for
Drug Evaluation and Research exclusivity board was
established to determine appropriate time frames of exclusivity
on a case to case basis for new drugs.182 Under the current
system, time frames of exclusivity may range from 180 days to
seven years.183 Patents play no role in the FDA’s decision to
grant exclusivity, placing the FDA in an excellent position to
grant a market monopoly of a similar nature to that of a patent
175. Id.
176. See id. at 11–12.
177. See id. at 13 (explaining that many drug development failures stem
from the failure to meet efficacy levels and that improving the understanding
of the underlying causes of these failures should increase the number of drugs
shown to be safe and effective).
178. 21 C.F.R. § 314.108 (2016) (stating that exclusivity does not require a
pre-existing patent and does not prolong the life of patents).
179. See generally Small Business Assistance: Frequently Asked Questions
for New Drug Product Exclusivity, U.S. FOOD& DRUG ADMIN., https://www.fda
.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ucm06996
2.htm (last visited Feb. 28, 2017).
180. See id.
181. See Renu Lal, Patents and Exclusivity, FDA/CDER SBIA CHRON., May
19, 2015, at 2–3, http://www.fda.gov/downloads/drugs/developmentapproval
process/smallbusinessassistance/ucm447307.pdf.
182. See id. at 3 (stating that the focus of the board is on “whether and what
type of exclusivity should be granted and the appropriate scope of exclusivity
grants”).
183. See id. at 2–3.
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without adhering to the rules that govern patentable subject
matter.
The FDA’s exclusivity system could easily be expanded to
include personalized medicine methods, creating an alternative
pathway to achieving a temporary market monopoly to
incentivize continued research in this field. The exclusivity
board would have to create new standards for determining
appropriate time frames of exclusivity, but could otherwise
continue functioning normally. In practice, a new personalized
medicine method could be granted FDA exclusivity protection
upon passing FDA regulations and prevent competitors from
immediately marketing a similar method. The period of
exclusivity would not last as long as a patent, but still would
provide additional peace of mind to researchers and be a viable
incentive to potentially replace that of a patent.
D. CASH INCENTIVE PROGRAM
Additionally, research on personalized medicine may be
further incentivized through establishing an incentive program
that offers cash rewards to researchers for their discoveries. A
prize system would incentivize researchers in the personalized
medicine profession to continue their work despite the financial
uncertainty associated with the inability to obtain a patent.184 It
would allow researchers to recoup the expenses incurred during
the research process without granting them patent protection.185
Offsetting research costs through prizes rather than patents
would also not impede the use of other discoveries within the
personalized medicine field.186
A cash incentive system would award prizes for
contributions to the field of personalized medicine, and prizes
are an extremely effective incentive. “After all, if there’s one
thing that defines modern economics, it’s that incentives matter,
184. See, e.g., Joesph E. Stiglitz, Prizes, Not Patents, PROJECT SYNDICATE
(Mar. 6, 2007), https://www.project-syndicate.org/print/prizes--not-patents
(arguing that prizes could be part of a portfolio of incentives including patents
which would encourage investment into drugs that have been overlooked by the
current system).
185. Id.
186. Id.
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and a prize is as obvious an incentive as one could imagine.”187
A prize system carries several distinct advantages in comparison
to the patent system. Primarily, as it relates to personalized
medicine, prizes may be awarded for research in areas typically
off limits for patent protection. Such capabilities would negate
the significance of Mayo in relation to the field of personalized
medicine.188 The flexibility of a prize system would allow the
government to incentivize research in any area of interest
without being restricted by the limitations of the patent
system.189 Prizes would also allow the government to set firm
boundaries on what discoveries would be eligible for the prize,
and thus grant greater specificity in what can be incentivized.
“A prize is for a particular accomplishment specified in advance,
while one can get a patent for anything that meets the relevant
statutory definition.”190 Specific areas of personalized medicine
most in need of technological development could therefore be
prioritized through granting larger prizes in those areas.
A prize system would be particularly beneficial for the field
of personalized medicine, asMayo has made it difficult to obtain
patents on diagnostic methods.191 The adoption of such a
monetary reward system has been previously considered to
compensate for shortcomings in the patent system.192 A prize
system was proposed for research on drugs and other healthcare
products by The Medical Innovation Prize Act of 2005 (MIPA).193
In this proposal, 0.5% of the country’s total GDP was to be pooled
each year to form a prize fund that could be awarded to
researchers.194 The goals established were “1) to provide
incentives for R&D investment in new and significantly better
187. Timothy J. Brennan, Prizes Versus Patents: A Comment on Jonathan
Adler’s Eyes on a Climate Prize: Rewarding Energy Innovation to Achieve
Climate Stabilization, 42 ENVTL. L. REP. NEWS& ANALYSIS 10719 (2012).
188. See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66,
66 (2012).
189. See Brennan, supra note 187, at 10720.
190. Id.
191. See Jenny Shmuel & Megan Chacon, Diagnostics Patent Eligibility: A
Turning Point Approaches, LIFE SCIS. INTELL. PROP. REV. at 4 (Jan. 27, 2016),
http://www.lifesciencesipreview.com/article/diagnostics-patent-eligibility-a-
turning-point-approaches.
192. Marlynn Wei, Should Prizes Replace Patents? A Critique of the Medical
Innovation Prize Act of 2005, 13 B.U. J. SCI. & TECH. L. 25, 25–26 (2007).
193. Id. at 28.
194. See id. (explaining that strict criteria would be established to determine
when a prize would be awarded).
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medicines; 2) to enhance access to medicines; and 3) to focus
more resources in non-profitable areas such as global infectious
diseases, ‘orphan drugs’ and neglected diseases.”195 The MIPA
was never approved by Congress,196 but substantially the same
system could be adopted as an alternative to patents in the field
of personalized medicine.
Several concerns with the MIPA lead to its ultimate
downfall in Congress. Primarily, there was a great deal of
uncertainty surrounding the abandonment of the patent system
utilized since the drafting of the United States Constitution in
favor of a prize system.197 A complete abandonment of the patent
system in favor of a prize system appeared too dramatic a
solution to many.198 A second issue raised in relation to a prize
system concerned determining the appropriate size of the
monetary reward.199 A fine line had to be established so that
prizes would be large enough to create a significant incentive for
researchers, without being so large as to be a significant
economic burden on the country.200 These issues would not be a
problem if a prize system were adopted for personalized
medicine, however, because the patent system would still be in
place and the prizes would merely act as a way to incentivize
areas of research not qualified for patent protection. Therefore,
the adoption of a prize system would likely be a significant form
of incentive for research in the field of personalized medicine
without impeding or abolishing the existing patent system.
E. COMPULSORY LICENSING
Personalized medicine may also benefit from the adoption of
a modified compulsory licensing system. Under such a system, a
type of pseudo-patent on personalized medicine methods could
195. See id. (stating that a prize system would allow for significant prizes
for large innovative contributions to society and lesser prizes for smaller
contributions).
196. H.R. 417-Medical Innovation Prize Act of 2005, CONGRESS.GOV, https://
www.congress.gov/bill/109th-congress/house-bill/417/all-actions (last visited
Mar. 3, 2017) (showing that the bill was last referred to the Subcommittee on
the Courts, the Internet, and Intellectual Property on Mar. 2, 2005).
197. SeeWei, supra note 192, at 31.
198. See id. at 32.
199. See id. at 32–33 (explaining that administrative difficulties were the
greatest roadblock to the prize system).
200. See id. (stating that excessive prize awards could lead to “resource
duplication and favoritism”).
2017] PERSONALIZED MEDICINE 817
be issued with the caveat that the patent is subject to mandatory
compulsory licensing. Compulsory licensing is a type of
exception to the exclusionary rights granted to the holder of a
patent.201 One form of compulsory licensing grants the
government the ability to convey licenses on patented inventions
to third parties without the consent of the patent holder.202 It
prevents patent holders from failing to utilize their patents
while also preventing competitors from benefiting from the
relevant invention.203 In such a situation, the government may
force the offending patent holder to license the invention to a
third party who may benefit from it.204 The United States has
never implemented a formal compulsory licensing scheme, but
many foreign countries have made use of compulsory licenses to
varying degrees.205 Compulsory licensing has been utilized
sparingly within the United States and only in relation to
matters of national interest, such as the Atomic Energy Act of
1948.206
Compulsory licenses have been criticized within the United
States for several reasons. First, the level of required patent
misuse that would allow a third party to obtain a compulsory
license is a fairly high standard to meet and would rarely occur,
making a compulsory licensing system largely useless.207 There
have been very few cases of patent suppression within the
United States due to the large time and monetary investment
required to obtain a patent in the first place.208 Second, it is
argued that forcing a compulsory license on a patent holder
would prevent them from recouping their research expenses and
201. Paul Gormley, Compulsory Patent Licenses and Environmental
Protection, 13 TUL. ENVTL. L.J. 131, 135–36 (1993).
202. See id.
203. See id.
204. See id. (explaining that compulsory licensing has also been used for
issues such as defense and security, in addition to atomic energy).
205. Cole M. Fauver, Compulsory Patent Licensing in the United States: An
Idea Whose Time Has Come, 8 NW. J. INT’L L. & BUS. 666, 674 (1988).
206. See id. at 670 n.21 (explaining that this provision was later amended to
eliminate the compulsory licensing portion).
207. See id. at 674–75.
208. See id. But see Cont’l Paper Bag Co. v. E. Paper Bag Co., 210 U.S. 405,
424–29 (1908) (showing one of the few instances where an important patent was
not sufficiently worked by the patent holder).
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devalue the entire patent system.209 This is particularly relevant
as compulsory licenses would play a large role in combating high
prices on products that are cheap to create, but stem from
expensive research and development investments.210 Lastly,
language from the Constitution is frequently cited to fight
compulsory licenses.211 Under Article I, Section 8 of the United
States Constitution, “The Congress shall have power . . . [t]o
promote the progress of science and useful arts, by securing for
limited times to authors and inventors the exclusive right to
their respective writings and discoveries.”212 This section states
that Congress may grant the “exclusive” rights of an invention
to the holder of the patent. It is argued that a constitutionally
backed exclusive right is not one that may be diminished
because the government thinks that right may be put to better
use elsewhere.213 These arguments have held compulsory
licensing at bay, and the United States has never adopted such
a system.
When applied to personalized medicine, however, there is a
more compelling argument for adopting a compulsory licensing
system. Incentivizing personalized medicine research through a
modified compulsory licensing system could be one way to
address the issue of unpatentability currently facing the
industry. The primary difference between the proposed system
and those adopted by other countries lies in the unpatentability
of personalized medicine methods. Mayo blocks the issuing of
patents on diagnostic methods, such as those employed in
personalized medicine, making it impossible to obtain a
compulsory license on a patent that doesn’t exist.214 However, if
a type of “pseudo-patent” (for lack of a better term) were to issue
on personalized medicine methods, under the caveat that the
pseudo-patent is subject to obligatory licensing, this issue may
be avoided.
209. See Gormley, supra note 201, at 136 (stating that the pharmaceutical
industry would be particularly vulnerable to these concerns due to the
substantial research costs associated with bringing a new drug to market).
210. See id.
211. See Fauver, supra note 205, at 677–78.
212. U.S CONST. art. I, § 8 (capitalization in original omitted).
213. See Fauver, supra note 205, at 678.
214. See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66,
92 (2012).
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Such a system would grant researchers the ability to obtain
some form of protection on their invention, but wouldn’t grant
them the ability to exclude others from utilizing it. Instead, if a
third party wished to work the patent, they could apply for a
compulsory license, given that specific criteria are met, and the
compulsory license would issue. The third party would then be
obligated to pay royalties to the holder of the pseudo-patent.
Furthermore, the societal detriments of market monopolies
would not exist, but the original inventor would still be placed in
a superior financial position to competitors from the royalties
collected. Thus there would still be a financial incentive to
conduct research in the field of personalized medicine, but there
would be no fear of granting a patent that essentially
monopolizes the underlying law of nature relied upon.
Pseudo-patents would also not run into any of the problems
associated with a regular compulsory licensing scheme as they
would fill in gaps where patents cannot issue in the first place.
The first argument against compulsory licensing would not
apply as it relates to the difficulty of proving that a patent holder
is failing to sufficiently utilize a patent. The second argument
would also be inapplicable as pseudo-patents would most
certainly help inventors recoup their losses through the royalty
payments received, whereas without a pseudo-patent scheme
they would have no additional source of income. Lastly, the
constitutional argument would not apply as it relates to the
rights of patent holders and pseudo-patents would be an entirely
different form of property right. Therefore, adoption of a
modified compulsory licensing scheme would provide strong
incentive for continued research on personalized medicine
without running afoul of the problems that typically plague such
a system.
IV. CONCLUSION
Personalized medicine has the potential to revolutionize the
current healthcare system and offers numerous benefits to
individuals seeking medical attention. However, Mayo presents
a road block to future development of technology in this field and
poses a significant threat to the future of personalized medicine.
To ensure the continued development of personalized medicine,
multiple solutions were proposed to either aid researchers in
obtaining patents on personalized medicine methods despite
Mayo, or to lessen the financial blow presented by the inability
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to obtain patent protection. Several or all proposed solutions
should be adopted to ensure that the field of personalized
medicine continues to develop and expand for the benefit of
society.
